WO2002079473A3 - Molecules utilisees a des fins diagnostiques et therapeutiques - Google Patents

Molecules utilisees a des fins diagnostiques et therapeutiques Download PDF

Info

Publication number
WO2002079473A3
WO2002079473A3 PCT/US2002/001009 US0201009W WO02079473A3 WO 2002079473 A3 WO2002079473 A3 WO 2002079473A3 US 0201009 W US0201009 W US 0201009W WO 02079473 A3 WO02079473 A3 WO 02079473A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithp
provides
therapeutics
diagnostics
diagnostic assays
Prior art date
Application number
PCT/US2002/001009
Other languages
English (en)
Other versions
WO2002079473A2 (fr
Inventor
Scott R Panzer
Stephen E Lincoln
Christina M Altus
Gerard E Dufour
Jennifer L Jackson
Anissa L Jones
Tam C Dam
Tommy F Liu
Bernard Harris
Vincent Flores
Abel Daffo
Rakesh Marwaha
Alice J Chen
Simon C Chang
Jr Edward H Gerstin
Careyna H Peralta
Marie H David
Samantha A Lewis
Original Assignee
Incyte Genomics Inc
Scott R Panzer
Stephen E Lincoln
Christina M Altus
Gerard E Dufour
Jennifer L Jackson
Anissa L Jones
Tam C Dam
Tommy F Liu
Bernard Harris
Vincent Flores
Abel Daffo
Rakesh Marwaha
Alice J Chen
Simon C Chang
Jr Edward H Gerstin
Careyna H Peralta
Marie H David
Samantha A Lewis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Scott R Panzer, Stephen E Lincoln, Christina M Altus, Gerard E Dufour, Jennifer L Jackson, Anissa L Jones, Tam C Dam, Tommy F Liu, Bernard Harris, Vincent Flores, Abel Daffo, Rakesh Marwaha, Alice J Chen, Simon C Chang, Jr Edward H Gerstin, Careyna H Peralta, Marie H David, Samantha A Lewis filed Critical Incyte Genomics Inc
Priority to US10/250,889 priority Critical patent/US20040115629A1/en
Priority to CA002434677A priority patent/CA2434677A1/fr
Priority to EP02733781A priority patent/EP1366166A2/fr
Publication of WO2002079473A2 publication Critical patent/WO2002079473A2/fr
Publication of WO2002079473A3 publication Critical patent/WO2002079473A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La présente invention concerne des polynucléotides humains purifiés utilisés à des fins diagnostiques et thérapeutiques (dithp). Elle concerne également des polypeptides (DITHP) codés par les dithp. De plus, l'invention concerne l'utilisation de dithp, ou de compléments de dithp, d'oligonucléotides ou de fragments d'oligonucléotide , pour des analyses diagnostiques. L'invention concerne en outre des vecteurs et des cellules hôtes renfermant des dithp pour l'expression de DITHP .Par ailleurs, cette invention porte sur l'emploi de DITHP isolés et purifiés dans le but de produire des anticorps anti-DITHP dans des tests de diagnostic. L'invention concerne enfin des microréseaux renfermant des dithp et leurs modes d'utilisation.
PCT/US2002/001009 2001-01-12 2002-01-09 Molecules utilisees a des fins diagnostiques et therapeutiques WO2002079473A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/250,889 US20040115629A1 (en) 2002-01-09 2002-01-09 Molecules for diagnostics and therapeutics
CA002434677A CA2434677A1 (fr) 2001-01-12 2002-01-09 Molecules utilisees a des fins diagnostiques et therapeutiques
EP02733781A EP1366166A2 (fr) 2001-01-12 2002-01-09 Molecules pour diagnose et therapie

Applications Claiming Priority (38)

Application Number Priority Date Filing Date Title
US26162201P 2001-01-12 2001-01-12
US60/261,622 2001-01-12
US26186501P 2001-01-16 2001-01-16
US26186401P 2001-01-16 2001-01-16
US60/261,865 2001-01-16
US60/261,864 2001-01-16
US26220901P 2001-01-17 2001-01-17
US26220801P 2001-01-17 2001-01-17
US26221501P 2001-01-17 2001-01-17
US26220701P 2001-01-17 2001-01-17
US26216401P 2001-01-17 2001-01-17
US60/262,207 2001-01-17
US60/262,209 2001-01-17
US60/262,208 2001-01-17
US60/262,215 2001-01-17
US60/262,164 2001-01-17
US26310201P 2001-01-18 2001-01-18
US60/263,102 2001-01-18
US26266201P 2001-01-19 2001-01-19
US26276001P 2001-01-19 2001-01-19
US26259901P 2001-01-19 2001-01-19
US26333001P 2001-01-19 2001-01-19
US26306401P 2001-01-19 2001-01-19
US26306301P 2001-01-19 2001-01-19
US26306501P 2001-01-19 2001-01-19
US26306901P 2001-01-19 2001-01-19
US26332901P 2001-01-19 2001-01-19
US26307701P 2001-01-19 2001-01-19
US60/262,662 2001-01-19
US60/263,065 2001-01-19
US60/262,760 2001-01-19
US60/263,077 2001-01-19
US60/263,069 2001-01-19
US60/262,599 2001-01-19
US60/263,064 2001-01-19
US60/263,329 2001-01-19
US60/263,063 2001-01-19
US60/263,330 2001-01-19

Publications (2)

Publication Number Publication Date
WO2002079473A2 WO2002079473A2 (fr) 2002-10-10
WO2002079473A3 true WO2002079473A3 (fr) 2003-10-02

Family

ID=27586320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001009 WO2002079473A2 (fr) 2001-01-12 2002-01-09 Molecules utilisees a des fins diagnostiques et therapeutiques

Country Status (3)

Country Link
EP (1) EP1366166A2 (fr)
CA (1) CA2434677A1 (fr)
WO (1) WO2002079473A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104169434A (zh) * 2011-12-20 2014-11-26 拜奥默里克斯公司 一种用于卵巢癌的体外诊断或预后的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036525A1 (fr) * 1998-01-19 1999-07-22 Shanghai Second Medical University Cbfblh12: gene fortement associe au gene ci-kfyi bovin pour complexe d'ubiquinone oxyreductase
WO1999056763A1 (fr) * 1998-05-07 1999-11-11 The Regents Of The University Of California Utilisation d'antigenes tissulaires cibles, negliges, pour moduler les reactions immunitaires
WO2001005422A2 (fr) * 1999-07-15 2001-01-25 Biomerieux Stelhys Utilisation d'un polypeptique pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique autoimmune
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036525A1 (fr) * 1998-01-19 1999-07-22 Shanghai Second Medical University Cbfblh12: gene fortement associe au gene ci-kfyi bovin pour complexe d'ubiquinone oxyreductase
WO1999056763A1 (fr) * 1998-05-07 1999-11-11 The Regents Of The University Of California Utilisation d'antigenes tissulaires cibles, negliges, pour moduler les reactions immunitaires
WO2001005422A2 (fr) * 1999-07-15 2001-01-25 Biomerieux Stelhys Utilisation d'un polypeptique pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique autoimmune
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EBI [online] 1 July 1989 (1989-07-01), XP002242621, Database accession no. p10745 *
DATABASE EMBL [online] 8 June 1996 (1996-06-08), HILLIER L ET AL: "The WashU-Merck EST project", XP002233817, Database accession no. W56292 *
DATABASE GENESEQ [online] 13 February 2002 (2002-02-13), XP002233818, Database accession no. AAS90994 *
LIOU G I ET AL: "HUMAN INTERSTITIAL RETINOID-BINDING PROTEIN GENE STRUCTURE AND PRIMARY SEQUENCE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 14, P10745, 1989, pages 8200 - 8206, XP002242620, ISSN: 0021-9258 *
TON CHRISTOPHER ET AL: "Identification and primary structure of five human NADH-ubiquinone oxidoreductase subunits.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 241, no. 2, 18 December 1997 (1997-12-18), pages 589 - 594, XP002233816, ISSN: 0006-291X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104169434A (zh) * 2011-12-20 2014-11-26 拜奥默里克斯公司 一种用于卵巢癌的体外诊断或预后的方法

Also Published As

Publication number Publication date
CA2434677A1 (fr) 2002-10-10
WO2002079473A2 (fr) 2002-10-10
EP1366166A2 (fr) 2003-12-03

Similar Documents

Publication Publication Date Title
WO2002097031A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2004023973A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2000073509A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002083876A3 (fr) Molecules secretoires
WO2005056600A3 (fr) Anticorps monoclonaux se liant ou neutralisant le virus de la dengue
WO2003020894A3 (fr) Facteur de transcription lie a l'insuline et utilisations de celui-ci
WO2002046228A3 (fr) Recepteur de la toxine du b. anthracis
WO2001068859A3 (fr) Molecules du type recepteur de l'interleukine 17 et leur utilisation
WO2001068705A3 (fr) Molecules du type recepteur de l'interleukine 17 et leurs utilisations
WO2002099080A3 (fr) Methodes de clonage d'adn, a faible pourcentage de clones negatifs, a l'aide d'oligonucleotides longs
WO2003062376A3 (fr) Molécules pour le diagnostic et la thérapeutique
WO2002040715A8 (fr) Molecules permettant la detection et le traitement de maladies
WO2002020756A3 (fr) Molécules sécrétoires
WO2001062927A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2003062385A3 (fr) Molecules secretoires
WO2001062922A3 (fr) Molecules destinees a la detection et au traitement de maladies
WO2002020754A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2004066933A3 (fr) Compositions et methodes permettant de traiter le cancer au moyen de igsf9 et de liv-1
WO2002055738A3 (fr) Molecules pour la detection et le traitement de maladies
WO2001062918A3 (fr) Molecules secretoires
WO2002079473A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002018576A3 (fr) Compositions et methodes associees aux genes specifiques du poumon
WO2001021836A3 (fr) Molecules pour le diagnostic et la therapeutique
WO2000075298A3 (fr) Molecules pour la detection et le traitement de maladies
WO2002057304A3 (fr) Molecules secretrices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2434677

Country of ref document: CA

Ref document number: 10250889

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002733781

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002733781

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002733781

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP